Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-cryptoxanthin
- Development stage
- Unknown
- Lead developer
- DSM Nutritional Products, Inc.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Beta-cryptoxanthin (BCX) is a naturally occurring oxygenated carotenoid (xanthophyll) and provitamin A precursor found in various fruits and vegetables, including tangerines, red peppers, and pumpkins. It acts as a potent antioxidant and exerts its biological effects primarily through the activation of the Nrf2/HO-1 signaling pathway, which mitigates oxidative stress, and the modulation of retinoic acid receptors (RAR) following its bioconversion into retinoids. BCX has been investigated for its potential therapeutic and preventive roles in metabolic and degenerative conditions such as diabetic kidney disease, age-related macular degeneration, diabetic retinopathy, osteoporosis, and pancreatic cancer. While it is widely available as a dietary supplement and has been the subject of clinical research by the Institute for Human Development and Potential (IHDP) and DSM Nutritional Products, it is not currently approved as a pharmaceutical drug.
- Other names
- BCXβ-cryptoxanthin(3R)-beta,beta-caroten-3-ol
02
Targets
HMOX1 (Heme oxygenase 1)ROS/1O2 (Reactive oxygen species / singlet oxygen in lipid membranes)RARA (Retinoic acid receptor alpha)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)RAR (Retinoic acid receptor)
Beyond the preview
Go deeper on beta-cryptoxanthin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-cryptoxanthin.